trending Market Intelligence /marketintelligence/en/news-insights/trending/wTSrXE06pe-5PZv6eIKO7g2 content esgSubNav
In This List

CytomX Therapeutics chairman to resign; replacement named

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


CytomX Therapeutics chairman to resign; replacement named

CytomX Therapeutics Inc. said Hoyoung Huh would step down as chairman, effective Dec. 31.

The company appointed President and CEO Sean McCarthy to replace Hoyoung as chairman and James Meyers as a board member.

Meyers serves as a director at Arbutus Biopharma Corp., a public biopharmaceutical company. In addition, he was executive vice president of worldwide commercial operations at Gilead Sciences Inc.

South San Francisco, Calif.-based CytomX Therapeutics operates as an oncology-focused biopharmaceutical company.